AstraZeneca

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company founded in 1999, partnering with SandboxAQ (Alphabet spinoff) in June 2023 to use quantum-inspired AI drug discovery and development tools reducing time and cost of bringing life-saving treatments to clinic. AstraZeneca uses SandboxAQ’s AQ-FEP software combining quantum mechanical equations accuracy with AI speed and power on classical computing hardware for treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. In June 2025, AstraZeneca joined collaborative research program with IonQ, AWS, and NVIDIA developing quantum-accelerated computational chemistry workflow delivering 20x speedup in time-to-solution compared to prior benchmarks. AstraZeneca applies quantum computing to molecular simulations, drug-target binding calculations, and pharmaceutical R&D optimization. AstraZeneca serves global pharmaceutical market requiring quantum-enhanced drug discovery, computational chemistry, and AI-accelerated pharmaceutical development for breakthrough treatments.

GSK Quantum

GlaxoSmithKline (GSK) is advancing quantum computing applications in pharmaceutical research through partnerships with IBM’s Quantum Heron and Condor processors for mRNA codon optimization and clinical data analysis, and collaboration with D-Wave for quantum annealing applications in genetic algorithms. The company worked with Capgemini UK and the National Quantum Computing Centre on quantum-enhanced drug discovery research, developing machine learning pipelines using quantum features for predicting targeted covalent drug reactivity. Led by Ross Walker, Global Director of Scientific Research Computing & Analytics, GSK participates in the QuPharm consortium alongside other major pharmaceutical companies to structure quantum computing’s potential in drug discovery, focusing on optimization problems that exceed traditional computational capabilities in messenger RNA research and therapeutic development.

Johnson & Johnson

Johnson & Johnson is an American multinational pharmaceutical and medical technologies corporation founded in 1886, with Janssen Pharmaceuticals subsidiary launching three-year research collaboration with Qu&Co in 2021 to develop and test quantum computational algorithms and software for pharmaceutical R&D applications. Janssen employed Qu&Co’s QUBEC platform for quantum computational chemistry and materials science, testing algorithms on quantum processors. In 2024, Johnson & Johnson partnered with Pasqal working to demonstrate practical benefits of quantum computing for drug discovery problems. Johnson & Johnson is among biggest pharma industry players submitting quantum computing patents alongside Merck, Roche, and Amgen. The company uses quantum computing for molecular simulations, optimization problems in drug discovery, and computational chemistry applications. Johnson & Johnson serves global pharmaceutical market requiring quantum-enhanced drug discovery, molecular modeling, and computational chemistry for developing treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions accelerating path from discovery to clinical trials.

Menten AI

Menten AI is a pioneering biotechnology company that combines quantum computing, artificial intelligence, and protein engineering to revolutionize drug discovery and design. Founded in 2018 by CEO Vikram Mulligan and leveraging research from the Baker Lab at the University of Washington, the company uses quantum-enhanced algorithms to solve complex protein folding and design problems that are computationally intractable for classical computers. Menten AI’s platform enables the design of novel protein therapeutics, including peptides and small proteins, by exploring vast sequence spaces and optimizing for desired properties such as stability, specificity, and manufacturability. The company’s quantum computing approach provides advantages in sampling complex conformational states and optimizing multi-objective design problems inherent in drug discovery. Menten AI has developed a pipeline of proprietary therapeutic candidates and offers computational design services to pharmaceutical partners. Their technology represents a convergence of quantum computing and biotechnology that could accelerate the development of new medicines for diseases including cancer, autoimmune disorders, and infectious diseases.

Merck Quantum

Merck & Co. explores quantum computing applications for pharmaceutical research, focusing on quantum algorithms for drug discovery, molecular modeling, and clinical trial optimization to accelerate therapeutic development. The company investigates quantum machine learning for analyzing complex biological data, protein-drug interactions, and personalized medicine approaches that could enhance pharmaceutical research capabilities. Merck collaborates with quantum computing companies and research institutions to leverage quantum advantages in computational chemistry, vaccine development, and therapeutic optimization, exploring quantum technologies that could improve drug discovery processes, reduce development timelines, and enhance therapeutic efficacy across oncology, immunology, and infectious disease research programs for advancing global health outcomes.

Novo Nordisk Quantum

Novo Nordisk explores quantum computing applications for pharmaceutical research and drug discovery, investigating quantum algorithms for molecular simulation, protein folding prediction, and drug optimization that could accelerate diabetes and obesity treatment development. The company researches quantum machine learning for analyzing clinical trial data, patient stratification, and personalized medicine approaches, exploring how quantum computing could enhance pharmaceutical research capabilities in endocrinology and metabolic diseases. Novo Nordisk collaborates with quantum computing companies and academic institutions to leverage quantum advantages in computational chemistry, biomarker discovery, and therapeutic development processes, contributing to the pharmaceutical industry’s adoption of quantum technologies for improving drug discovery timelines and therapeutic outcomes in diabetes care and chronic disease management.

ProteinQure

ProteinQure leverages quantum molecular simulations and AI to accelerate drug discovery and development, using quantum-enhanced computational methods to model complex molecular interactions and protein dynamics that are challenging for classical computers, enabling more accurate predictions of drug efficacy and safety for pharmaceutical applications.

Company Information

• Founded: 2017
• Country: Canada
• Website: https://proteinqure.com
• Categories: quantum pharma

Related Companies

Explore other quantum computing companies in similar categories or regions.

← Back to All Companies

QuantumBio

QuantumBio is a software and services company providing computational chemistry and structural biology solutions for pharmaceutical, biotech, and academic drug discovery. The company leverages quantum mechanical approaches with proprietary XModeScore technology for X-ray and cryo-EM structure refinement, high-throughput computer-aided drug design, and precision molecular modeling to enhance understanding of biochemical structure and function. QuantumBio serves the life sciences research community with quantum physics-based computational chemistry tools.

Company Information

• Founded: 2002
• Country: United States
• Website: https://www.quantumbioinc.com
• Categories: quantum software, quantum pharma

Related Companies

Explore other quantum computing companies in similar categories or regions.

Resolve Stroke

Resolve Stroke is an Israeli medical technology company applying quantum computing and AI to stroke treatment and prevention. The company uses quantum-enhanced machine learning to analyze medical imaging data and predict stroke risk, enabling earlier intervention and personalized treatment plans. Resolve Stroke is backed by Quantonation and collaborates with leading medical institutions.

Company Information

• Founded: 2023
• Country: Israel
• Website: https://resolvestroke.com
• Categories: quantum pharma, quantum ai

Related Companies

Explore other quantum computing companies in similar categories or regions.

XtalPi

XtalPi is an AI-driven drug discovery company leveraging quantum physics algorithms, artificial intelligence, and robotics to accelerate pharmaceutical research. Founded by three MIT quantum physicists, the company uses quantum calculations for molecular structures to train proprietary AI large language models that screen billions of molecules for drug candidates, increasing chemical experiment success rates from 20-30% to 90%. XtalPi serves nearly 80% of global big pharma including Pfizer, Eli Lilly, Johnson & Johnson, and Merck, with a $6 billion collaboration with DoveTree Medicines announced in 2025.